000850812 001__ 850812
000850812 005__ 20210129234634.0
000850812 0247_ $$2doi$$a10.23736/S1824-4785.18.03105-9
000850812 0247_ $$2pmid$$apmid:29869489
000850812 0247_ $$2WOS$$aWOS:000445240400007
000850812 0247_ $$2altmetric$$aaltmetric:43363255
000850812 037__ $$aFZJ-2018-04583
000850812 041__ $$aEnglish
000850812 082__ $$a570
000850812 1001_ $$0P:(DE-HGF)0$$aChoudhary, G.$$b0
000850812 245__ $$aInvestigational PET tracers for High-grade Gliomas.
000850812 260__ $$aTorino$$bEd. Minerva Medica$$c2018
000850812 3367_ $$2DRIVER$$aarticle
000850812 3367_ $$2DataCite$$aOutput Types/Journal article
000850812 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1536836154_30555
000850812 3367_ $$2BibTeX$$aARTICLE
000850812 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000850812 3367_ $$00$$2EndNote$$aJournal Article
000850812 520__ $$aHigh-grade gliomas (HGGs) are the most common primary malignant tumors of the brain, with glioblastoma (GBM) constituting over 50% of all the gliomas in adults. The disease carries very high mortality, and even with optimal treatment, the median survival is 2-5 years for anaplastic tumors and 1-2 years for GBMs. Neuroimaging is critical to managing patients with HGG for diagnosis, treatment planning, response assessment, and detecting recurrent disease. Magnetic resonance imaging (MRI) is the cornerstone of imaging in neuro-oncology, but molecular imaging with positron emission tomography (PET) can overcome some of the inherent limitations of MRI. Additionally, PET has the potential to target metabolic and molecular alterations in HGGs relevant to prognosis and therapy that cannot be assessed with anatomic imaging. Many classes of PET tracers have been evaluated in HGG including agents that target cell membrane biosynthesis, protein synthesis, amino acid transport, DNA synthesis, the tricarboxylic acid (TCA) cycle, hypoxic environments, cell surface receptors, blood flow, vascular endothelial growth factor (VEGF), epidermal growth factor (EGFR), and the 18-kDa translocator protein (TSPO), among others. This chapter will provide an overview of PET tracers for HGG that have been evaluated in human subjects with a focus on tracers that are not yet in widespread use for neuro-oncology.
000850812 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000850812 7001_ $$0P:(DE-Juel1)131777$$aLangen, K. J.$$b1
000850812 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, N.$$b2
000850812 7001_ $$0P:(DE-HGF)0$$aMcconathy, J.$$b3$$eCorresponding author
000850812 773__ $$0PERI:(DE-600)2083933-9$$a10.23736/S1824-4785.18.03105-9$$n3$$p281-94$$tThe quarterly journal of nuclear medicine and molecular imaging$$v62$$x0392-0208$$y2018
000850812 909CO $$ooai:juser.fz-juelich.de:850812$$pVDB
000850812 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b1$$kFZJ
000850812 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b2$$kFZJ
000850812 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000850812 9141_ $$y2018
000850812 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000850812 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000850812 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000850812 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000850812 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000850812 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000850812 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000850812 920__ $$lyes
000850812 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000850812 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000850812 980__ $$ajournal
000850812 980__ $$aVDB
000850812 980__ $$aI:(DE-Juel1)INM-3-20090406
000850812 980__ $$aI:(DE-Juel1)INM-4-20090406
000850812 980__ $$aUNRESTRICTED